Krka’s management discussed the firm’s latest perception of the European biosimilars market, as it reported financial results for the nine months to 30 September.
Krka Group continues to have no plans to develop biosimilars in-house, noting the amount of risk involved for what it perceives as insufficient returns amid an unfavorable payer market, but will target partnered projects to eventually create a portfolio.
“We will cooperate on specific projects on biosimilars with our strategic partners where we can provide an essential role in regulatory affairs, sales and marketing,” management
Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.
With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.
Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.
